Zobrazeno 1 - 10 of 283 pro vyhledávání: '"Richard Béliveau"'
2
Akademický článek
Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing
Autor: Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Véronique Lullier, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Frontiers in Immunology, Vol 15 (2024)
The anticancer efficacy of Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate internalized through a sortilin-mediated process, was assessed in a triple-negative breast cancer-derived MDA-MB-231 immunocompromised xenograft tumor model where
Externí odkaz: https://doaj.org/article/406adb6e515441f688e79a799ed206ee
Zobrazit plný text záznamu
3
Akademický článek
New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells
Autor: Cyndia Charfi, Michel Demeule, Jean-Christophe Currie, Alain Larocque, Alain Zgheib, Bogdan Alexandru Danalache, Amira Ouanouki, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Frontiers in Oncology, Vol 11 (2021)
Vasculogenic mimicry (VM) is defined as the formation of microvascular channels by genetically deregulated cancer cells and is often associated with high tumor grade and cancer therapy resistance. This microcirculation system, independent of endothel
Externí odkaz: https://doaj.org/article/9856283e5a394452a64411b0a22a4d2f
Zobrazit plný text záznamu
4
Akademický článek
The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells
Autor: Michel Demeule, Cyndia Charfi, Jean-Christophe Currie, Alain Zgheib, Bogdan Alexandru Danalache, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Pharmaceutics, Vol 14, Iss 9, p 1910 (2022)
Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Whe
Externí odkaz: https://doaj.org/article/0b8a08e7364d4c5baf46b5c7fe2801e9
Zobrazit plný text záznamu
6
Akademický článek
[Untitled]
Autor: Borhane Annabi, Simon Lord-Dufour, Amélie Vézina, Richard Béliveau
Publikováno v: Drug Target Insights, Vol 6, Iss 1 (2012)
Abstract non disponibile
Externí odkaz: https://doaj.org/article/16d9f057753a4d67b03a702c4015d7a6
Zobrazit plný text záznamu
7
Abstract 4499: The peptide-drug conjugate sudocetaxel zendusortide (TH1902) potentiates anti-tumoral activity of the anti-PD-L1 checkpoint inhibitor and induces immune cell infiltration in a B16-F10 syngeneic melanoma model
Autor: Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Cancer Research. 83:4499-4499
Tumor-infiltrating immune cells are involved in the control of cancer and are closely related to clinical outcomes. Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate (PDC) of the sortilin (SORT1)-binding peptide TH19P01 ester-linked to two
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4cdaa33b4400848c4fa428fec9c7d21d
https://doi.org/10.1158/1538-7445.am2023-4499
Zobrazit plný text záznamu
8
Abstract 4493: Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers
Autor: Cyndia Charfi, Michel Demeule, Jean-Christophe Currie, Alain Zgheib, Bogdan Alexandru Danalache, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Cancer Research. 83:4493-4493
Over the last decade, the targeting of specific cell surface receptors such as human epidermal growth factor receptor 2 (Her2) in breast cancer cells has allowed the emergence of innovative strategies for the delivery of anticancer agents. High expre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a24ce882dd8efb53825e5d1914172b07
https://doi.org/10.1158/1538-7445.am2023-4493
Zobrazit plný text záznamu
9
Abstract P3-10-07: Receptor-mediated chemotherapy using a new Docetaxel-peptide conjugate for Sortilin-positive triple-negative breast cancer
Autor: Borhane Annabi, Cyndia Charfi, Jean-Christophe Currie, Alain Zgheib, Alain Larocque, Richard Béliveau, Christian Marsolais, Michel Demeule
Publikováno v: Cancer Research. 80:P3-10
Background: Triple-negative breast cancer (TNBC) still lacks defined molecular biomarkers. Thus, targeting of specific gene/protein molecular signature of tumors emerged among the best anticancer strategies. Recently, increased expression of the cell
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c1f4731218349aba7e7a889967cbd2a
https://doi.org/10.1158/1538-7445.sabcs19-p3-10-07
Zobrazit plný text záznamu
10
The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers
Autor: Jean-Christophe Currie, Michel Demeule, Cyndia Charfi, Alain Zgheib, Alain Larocque, Bogdan Alexandru Danalache, Amira Ouanouki, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Cancers; Volume 14; Issue 8; Pages: 1877
Sortilin (SORT1) receptor-mediated endocytosis functions were exploited for this new approach for effective and safe treatments of gynecological cancers. Here, high expression of SORT1 was found in >75% of the clinically annotated ovarian and endomet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292385f8601ef91425611e3e53d2bcde
https://pubmed.ncbi.nlm.nih.gov/35454785
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje